Evidence map›Paper›PMID 37878861›Full record

ArticleACS infectious diseases2023

Integrated Transcriptomic and Metabolomic Mapping Reveals the Mechanism of Action of Ceftazidime/Avibactam against Pan-Drug-Resistant

Maytham Hussein, Rafah Allobawi, Jinxin Zhao, Heidi Yu, Stephanie L Neville, Jonathan Wilksch, Labell J M Wong, Mark Baker, Christopher A McDevitt, Gauri G Rao and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Maytham HusseinMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0001-5922-7312
Rafah AllobawiMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.
Jinxin ZhaoMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.
Heidi YuMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.
Stephanie L NevilleDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3010, Australia.
Jonathan WilkschDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3010, Australia.
Labell J M WongMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.
Mark BakerDiscipline of Biological Sciences, Priority Research Centre in Reproductive Biology, Faculty of Science and IT, University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.
Christopher A McDevittDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3010, Australia.ORCID 0000-0003-1596-4841
Gauri G RaoDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7355, United States.ORCID 0000-0002-8704-7770
Jian LiMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0001-7953-8230
Tony VelkovMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0002-0017-7952
Australian Regenerative Medicine Institute · AUThe University of Melbourne · AUUniversity of Newcastle Australia · AUUniversity of North Carolina at Chapel Hill · US

Funding

Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’R01AI170889 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MALONEY, SARA ELIZABETH, RAO, GAURI G · 2022 to 2025
$3.8M
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approachR01AI146241 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RAO, GAURI G, VELKOV, TONY · 2019 to 2023
$3.0M
NIAID NIH HHS R01 AI146241NIAID NIH HHS R01 AI170889
6 · The paper itself

Abstract

Here, we employed an integrated metabolomics and transcriptomics approach to investigate the molecular mechanism(s) of action of ceftazidime/avibactam against a pan-drug-resistant

Indexed as

CeftazidimeKlebsiella InfectionsAnti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesCarbonGene Expression ProfilingHumansKlebsiella pneumoniaeLipopolysaccharidesPeptidoglycanTranscriptomeAnti-Bacterial AgentsavibactamAzabicyclo Compoundsbeta-LactamasesCarbonCeftazidimeLipopolysaccharidesPeptidoglycanantimicrobial resistanceceftazidime-avibactamK. pneumoniaemetabolomicstranscriptomics

Identifiers

PMID37878861
PMCPMC10714405
OpenAlexW4387934221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.